{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:34:52Z","timestamp":1762032892885},"reference-count":48,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Bill & Melinda Gates Foundation, the Foundation for the National Institutes of Health through the Grand Challenges in Global Health initiative (ID #334), the Marie-Josee and Henry Kravis Fellowship at The Rockefeller University, the Greenberg Medical Research Institute and the Starr Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.vaccine.2010.06.052","type":"journal-article","created":{"date-parts":[[2010,6,30]],"date-time":"2010-06-30T09:20:54Z","timestamp":1277889654000},"page":"5676-5685","source":"Crossref","is-referenced-by-count":27,"title":["Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development"],"prefix":"10.1016","volume":"28","author":[{"given":"David","family":"Franco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Qing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina T.","family":"Stoyanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Moran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles M.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David D.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2010.06.052_bib1","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1172\/JCI34706","article-title":"The spread, treatment, and prevention of HIV-1: evolution of a global epidemic","volume":"118","author":"Cohen","year":"2008","journal-title":"J Clin Invest"},{"issue":"9653","key":"10.1016\/j.vaccine.2010.06.052_bib2","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(08)61592-5","article-title":"HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis","volume":"372","author":"McElrath","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2010.06.052_bib3","series-title":"Vaccines","first-page":"1095","article-title":"Yellow fever vaccine","author":"Monath","year":"2004"},{"key":"10.1016\/j.vaccine.2010.06.052_bib4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1006\/viro.2001.1255","article-title":"Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E","volume":"293","author":"Co","year":"2002","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.vaccine.2010.06.052_bib5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1084\/jem.20051720","article-title":"Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity","volume":"203","author":"Querec","year":"2006","journal-title":"J Exp Med"},{"issue":"22","key":"10.1016\/j.vaccine.2010.06.052_bib6","doi-asserted-by":"crossref","first-page":"12497","DOI":"10.1128\/JVI.78.22.12497-12507.2004","article-title":"ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy","volume":"78","author":"Arroyo","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2010.06.052_bib7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4269\/ajtmh.2005.72.74","article-title":"Replication of chimeric yellow fever virus-dengue serotypes 1\u20134 virus vaccine strains in dendritic and hepatic cells","volume":"72","author":"Brandler","year":"2005","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"10.1016\/j.vaccine.2010.06.052_bib8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4161\/hv.1.3.1797","article-title":"Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax-JE) in non-human primates","volume":"1","author":"Dean","year":"2005","journal-title":"Hum Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2010.06.052_bib9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/hv.2.2.2555","article-title":"Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes","volume":"2","author":"Guirakhoo","year":"2006","journal-title":"Hum Vaccine"},{"key":"10.1016\/j.vaccine.2010.06.052_bib10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0065-3527(03)61013-4","article-title":"Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis","volume":"61","author":"Lai","year":"2003","journal-title":"Adv Virus Res"},{"issue":"17","key":"10.1016\/j.vaccine.2010.06.052_bib11","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1073\/pnas.0601932103","article-title":"A live, attenuated recombinant West Nile virus vaccine","volume":"103","author":"Monath","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2010.06.052_bib12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/01.qco.0000178823.28585.ad","article-title":"New developments in flavivirus vaccines with special attention to yellow fever","volume":"18","author":"Pugachev","year":"2005","journal-title":"Curr Opin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2010.06.052_bib13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.virol.2005.12.001","article-title":"A recombinant yellow fever 17D vaccine expressing Lassa virus glycoproteins","volume":"345","author":"Bredenbeek","year":"2006","journal-title":"Virology"},{"issue":"7","key":"10.1016\/j.vaccine.2010.06.052_bib14","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1128\/JVI.02255-09","article-title":"Recombinant yellow fever vaccine virus 17D expressing SIVmac239 Gag induces SIV-specific CD8+ T cell responses in rhesus macaques","volume":"84","author":"Bonaldo","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2010.06.052_bib15","first-page":"285","article-title":"Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation","volume":"1","author":"Rice","year":"1989","journal-title":"New Biol"},{"issue":"5","key":"10.1016\/j.vaccine.2010.06.052_bib16","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1128\/JVI.78.5.2414-2425.2004","article-title":"Uncleaved NS2-3 is required for production of infectious bovine viral diarrhea virus","volume":"78","author":"Agapov","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2010.06.052_bib17","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1128\/JVI.80.4.1734-1741.2006","article-title":"Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry","volume":"80","author":"Tscherne","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2010.06.052_bib18","doi-asserted-by":"crossref","first-page":"8083","DOI":"10.1128\/JVI.73.10.8083-8094.1999","article-title":"Mutagenesis of the NS2B-NS3-mediated cleavage site in the flavivirus capsid protein demonstrates a requirement for coordinated processing","volume":"73","author":"Amberg","year":"1999","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2010.06.052_bib19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.virol.2008.04.043","article-title":"Comprehensive analysis of T cell epitope discovery strategies using 17DD yellow fever virus structural proteins and BALB\/c (H2d) mice model","volume":"378","author":"Maciel","year":"2008","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.vaccine.2010.06.052_bib20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1128\/CVI.00078-07","article-title":"Evaluation of an indirect immunofluorescence assay for detection of immunoglobulin M (IgM) and IgG antibodies against yellow fever virus","volume":"15","author":"Niedrig","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2010.06.052_bib21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1743-422X-4-115","article-title":"Construction and characterization of recombinant flaviviruses bearing insertions between E and NS1 genes","volume":"30","author":"Ronaldo","year":"2007","journal-title":"Virol J"},{"issue":"3","key":"10.1016\/j.vaccine.2010.06.052_bib22","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1128\/JVI.77.3.2265-2270.2003","article-title":"Fine mapping of a cis-acting sequence element in yellow fever virus RNA that is required for RNA replication and cyclization","volume":"77","author":"Corver","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2010.06.052_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0022-2836(87)90455-4","article-title":"Conserved elements in the 3\u2032 untranslated region of flavivirus RNAs and potential cyclization sequences","volume":"198","author":"Hahn","year":"1987","journal-title":"J Mol Biol"},{"key":"10.1016\/j.vaccine.2010.06.052_bib24","doi-asserted-by":"crossref","first-page":"6719","DOI":"10.1128\/JVI.75.14.6719-6728.2001","article-title":"Essential role of cyclization sequences in flavivirus RNA replication","volume":"75","author":"Khromykh","year":"2001","journal-title":"J Virol"},{"issue":"5090","key":"10.1016\/j.vaccine.2010.06.052_bib25","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.1470917","article-title":"Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene","volume":"258","author":"Daniel","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2010.06.052_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0042-6822(03)00583-X","article-title":"Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys","volume":"316","author":"Marchevsky","year":"2003","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.vaccine.2010.06.052_bib27","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.immuni.2008.02.020","article-title":"Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines","volume":"28","author":"Miller","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2010.06.052_bib28","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1006\/jmbi.2001.5258","article-title":"Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus","volume":"315","author":"Bonaldo","year":"2002","journal-title":"J Mol Biol"},{"issue":"2","key":"10.1016\/j.vaccine.2010.06.052_bib29","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1084\/jem.20041526","article-title":"Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model","volume":"201","author":"Tao","year":"2005","journal-title":"J Exp Med"},{"issue":"9","key":"10.1016\/j.vaccine.2010.06.052_bib30","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1084\/jem.20051352","article-title":"Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes","volume":"202","author":"Barba-Spaeth","year":"2005","journal-title":"J Exp Med"},{"issue":"19","key":"10.1016\/j.vaccine.2010.06.052_bib31","doi-asserted-by":"crossref","first-page":"9197","DOI":"10.1128\/JVI.74.19.9197-9205.2000","article-title":"Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases","volume":"74","author":"McAllister","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2010.06.052_bib32","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11908-996-0005-9","article-title":"Current assessment of yellow fever and yellow fever vaccine","volume":"6","author":"Lefeuvre","year":"2004","journal-title":"Curr Infect Dis Rep"},{"issue":"13","key":"10.1016\/j.vaccine.2010.06.052_bib33","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1084\/jem.20082292","article-title":"Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses","volume":"205","author":"Gaucher","year":"2008","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.vaccine.2010.06.052_bib34","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ni.1688","article-title":"Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans","volume":"10","author":"Querec","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2010.06.052_bib35","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nri2016","article-title":"HIV: bigger T-cell response not necessarily better","volume":"7","author":"Minton","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2010.06.052_bib36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nm1520","article-title":"CD8+ T-cell responses to different HIV proteins have discordant associations with viral load","volume":"13","author":"Kiepiela","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2010.06.052_bib37","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1128\/JVI.78.9.4463-4477.2004","article-title":"Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides","volume":"78","author":"Kaufmann","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2010.06.052_bib38","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1128\/JVI.77.3.2081-2092.2003","article-title":"Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load","volume":"77","author":"Addo","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2010.06.052_bib39","doi-asserted-by":"crossref","first-page":"11983","DOI":"10.1128\/JVI.75.24.11983-11991.2001","article-title":"Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection","volume":"75","author":"Betts","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2010.06.052_bib40","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1128\/JVI.78.7.3233-3243.2004","article-title":"Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load","volume":"78","author":"Masemola","year":"2004","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2010.06.052_bib41","doi-asserted-by":"crossref","first-page":"e1424","DOI":"10.1371\/journal.pone.0001424","article-title":"Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads","volume":"3","author":"Rolland","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2010.06.052_bib42","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.1128\/JVI.77.12.6867-6878.2003","article-title":"Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection","volume":"77","author":"Cao","year":"2003","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2010.06.052_bib43","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1586\/erv.09.94","article-title":"Development of more efficient and effective DNA vaccines","volume":"8","author":"Apostolopoulos","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"32","key":"10.1016\/j.vaccine.2010.06.052_bib44","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1016\/j.vaccine.2009.01.137","article-title":"Co-immunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII","volume":"27","author":"Ramanathan","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2010.06.052_bib45","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.virol.2009.07.017","article-title":"High dose of plasmid IL-15 inhibits immune responses in an influenza non-human primates immunogenicity model","volume":"393","author":"Yin","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2010.06.052_bib46","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1084\/jem.20052005","article-title":"Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine","volume":"203","author":"Trumpfheller","year":"2006","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.vaccine.2010.06.052_bib47","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri2274","article-title":"T-cell quality in memory and protection: implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2010.06.052_bib48","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1592","article-title":"Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major","volume":"13","author":"Darrah","year":"2007","journal-title":"Nat Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10008637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10008637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T08:03:41Z","timestamp":1591430621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10008637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":48,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0264410X10008637"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.06.052","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}